Taysha Gene Therapies, Inc.
TSHA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,006,089 | $599,440 | $325,983 | $376,836 |
| - Cash | $297,344 | $312,761 | $116,593 | $139,036 |
| + Debt | $16,506 | $59,597 | $61,354 | $63,180 |
| Enterprise Value | $725,251 | $346,276 | $270,744 | $300,980 |
| Revenue | $0 | $1,986 | $2,302 | $2,022 |
| % Growth | -100% | -13.7% | 13.8% | – |
| Gross Profit | -$286 | $1,986 | $2,302 | $2,022 |
| % Margin | – | 100% | 100% | 100% |
| EBITDA | -$32,432 | -$26,588 | -$21,227 | -$18,459 |
| % Margin | – | -1,338.8% | -922.1% | -912.9% |
| Net Income | -$32,733 | -$26,882 | -$21,529 | -$18,785 |
| % Margin | – | -1,353.6% | -935.2% | -929% |
| EPS Diluted | -0.093 | -0.09 | -0.08 | -0.092 |
| % Growth | -2.7% | -12.9% | 12.9% | – |
| Operating Cash Flow | -$24,166 | -$20,182 | -$22,020 | -$18,308 |
| Capital Expenditures | -$108 | -$2 | -$378 | $2 |
| Free Cash Flow | -$24,274 | -$20,184 | -$22,398 | -$18,306 |